Health economic analyses of the Global Programme to Eliminate Lymphatic Filariasis

Hugo C. Turner

MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, St Mary’s Campus, Imperial College London, Norfolk Place, London, W2 1PG, UK

*Corresponding author: Tel: +44 20 7594 3246; E-mail: hugo.turner@imperial.ac.uk

Received 20 April 2020; revised 30 July 2020; editorial decision 22 October 2020; accepted 19 November 2020

The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was established by the WHO in 2000. It aims to eliminate lymphatic filariasis as a public health problem. This paper summarises the key estimates of the cost-effectiveness and economic benefits related to the mass drug administration (MDA) provided by the GPELF. Several studies have investigated the cost-effectiveness of this MDA, estimating the cost per disability-adjusted life year (DALY) averted. These cost-effectiveness estimates have consistently classed the intervention as cost-effective and as favourable compared with other public health interventions conducted in low- and middle-income countries. Studies have also found that the MDA used for lymphatic filariasis control generates significant economic benefits. Although these studies are positive, there are still important gaps that warrant further health economic research (particularly, the evaluation of alternative interventions, further evaluation of morbidity management strategies and evaluation of interventions for settings coendemic with Loa loa). To conclude, health economic studies for a programme as large as the GPELF are subject to uncertainty. That said, the GPELF has consistently been estimated to be cost-effective and to generate notable economic benefits by a number of independent studies.

Keywords: cost-effectiveness, economic benefits, GPELF, health economics, lymphatic filariasis.

Introduction

The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was established by the WHO in 2000. Since the start of the programme, > 7 billion mass drug administration (MDA) treatments have been delivered with > 558.5 million people treated in 2018 alone. This level of intervention requires significant investment. Health economic analyses are an important element of decision-making within global health and are key for showing that the costs of the programme are worth its benefit.

The aim of this paper is to summarise the key estimates of the cost-effectiveness and economic benefits related to MDA provided by the GPELF, as well as to highlight remaining health economic research needs. Further details on the health economic studies conducted for lymphatic filariasis can be found in the systematic review by Gedge et al.

The costs of MDA

Estimates of the costs of MDA are a vital component for subsequent economic evaluations. Notably, country programmes and local researchers have a vital role in cost studies, without which economic evaluations would not be possible.

The economic cost of MDA varies between different countries depending on several factors, such as if volunteers are used, the salaries of healthcare personnel, which drug combinations are used and the size of the targeted population. Turner et al. estimated the average costs of the treatments given by the GPELF between 2000 and 2014 using a website-based regression model for MDA delivery costs developed by the WHO. The authors estimated that the average economic cost per treatment (without and with the value of the donated drugs)...
was US$0.56 (95% CI 0.25 to 0.94) and US$1.32 (95% CI 1.00 to 1.69), respectively (2014 prices). However, this was an overall average for the programme and the costs of MDA delivery varied across different settings.1

**Estimates of the cost-effectiveness of the GPELF**

Cost-effectiveness analysis is a form of economic analysis that compares the relative costs and effectiveness of different courses of action. Several studies have investigated the cost-effectiveness of MDA provided under the GPELF, estimating the cost per disability-adjusted life year (DALY) averted (one DALY can be thought of as 1 y of ‘healthy’ life lost).

Turner et al.3 estimated the cost-effectiveness of the GPELF based on the costs and long-term health benefits resulting from the MDA delivered between 2000 and 2014. The cost per DALY averted when using economic costs was estimated to be US$29 (US$14–48) excluding the value of the donated drugs and US$64 (US$49–83) including the value of the donated drugs (2014 prices). This is consistent with other estimates. For example, analysis within the second edition of the Disease Control Priorities in Developing Countries project5 estimated lymphatic filariasis-related MDA costs of approximately US$29 per DALY averted within a control scenario and between US$4.40 and US$8.10 per DALY averted under elimination scenarios. In addition, Stone et al.9 estimated the incremental cost-effectiveness of three different scenarios for accelerating the rate of MDA coverage scale-up within an eradication investment case. These varied between US$73–219 per incremental DALY averted (2012 prices).

Differences across these estimates could be due to various factors, such as how the costs of the programme were estimated and the approach used to estimate the number of DALYs averted.4 Regardless, these cost-effectiveness estimates are highly favourable compared with other public health interventions conducted in low- and middle-income countries.10 The correct cost-effectiveness thresholds (that class an intervention as cost-effective or not) to use in such settings are currently under debate.11–15 However, the estimates related to the GPELF appear to be robust to this, even when conservative thresholds are used.

It should be noted that these estimates are typical for the GPELF as a whole. However, there are settings where the costs of MDA are much higher and therefore the cost-effectiveness is lower. This is particularly relevant for countries that treat small populations, such as programmes on small islands.7 Consequently, the cost-effectiveness of MDA programmes will depend on the local context and will be influenced by the epidemiological setting as well as political, economic and health system conditions. For example, the cost-effectiveness of MDA was estimated to be lower in settings coadministering ivermectin and albendazole as opposed to diethylcarbamazine and albendazole, due to the higher economic value of ivermectin.3

The backbone of the GPELF is the significant drug donations from the pharmaceutical industry.16 However, how to correctly value these donations in the context of an economic evaluation is debatable and a source of variation between different studies.4,17

**Economic benefits and cost-benefit of the GPELF**

The clinical disease caused by lymphatic filariasis is known to have a notable impact on patients’ productivity18 and, furthermore, the disease has been shown to have an notable economic burden.19–21 For example, prior to MDA programmes, lymphatic filariasis was estimated to have a corresponding annual economic burden of US$5.77 billion (2016 prices).21

Several studies have looked at the economic benefits of MDA delivered by the GPELF.22–24 These studies translate the health benefits of MDA into monetary terms.

Turner et al.22 estimated the long-term economic benefits of the MDA treatments delivered by the GPELF (an update of the 2000–2007 analysis performed by Chu et al.23), projecting that US$100.5 billion (2014 prices) would potentially be gained over the lifetimes of those who received treatment between 2000 and 2014. A subsequent cost-benefit analysis (that compared the estimated economic benefits with the cost of the intervention) estimated that the benefit-cost ratio of these treatments varied between 30 (18–63) and 14 (11–18) when using economic costs, including and excluding the value of the donated drugs, respectively (2014 prices).3

Redekop et al.24 estimated that achieving the WHO 2020 targets between 2011 and 2030 would generate US$24.3 billion (2005 prices) in averted productivity losses over this time period.

It is important to note that these types of economic benefit estimates are directly related to the assumed precontrol number of clinical cases and the number of cases estimated to be averted by MDA. Averted productivity losses consistently made up the majority of the estimated economic benefits across the different studies. However, these estimates depend on several assumptions, such as the effect of clinical disease on productivity,18 the number of years of productive life lived with clinical disease, employment rates and wage rates. These estimates are also particularly uncertain for those in informal employment, which applies to many individuals with clinical lymphatic filariasis. Furthermore, when estimating these productivity costs, these studies have used the human capital approach, which takes the patient’s point of view when valuing lost productivity and therefore counts all the work they miss carrying out as a productivity loss.5,22 Consequently, this approach estimates potential rather than experienced productivity losses, and the proportion of estimated economic benefits that are actually realisable to endemic countries’ economies is uncertain. However, the conclusion that the GPELF generates notable economic benefits seems robust to this uncertainty.

Other studies have also highlighted the importance of the productivity losses associated with lymphatic filariasis-related morbidity.6,25 For example, it was estimated that in India, 3.8–8% of the potential male labour input was being lost due to lymphatic filariasis-related morbidity.26,27 This was subsequently valued at US$704 million per year (1995 prices).19 Similarly, a study in Ghana estimated that >7% of potential male labour was being lost due to chronic lymphatic filariasis morbidity.20 This further highlights the potential impact on endemic countries’ economies and the significant benefits of the programme.
Future health economic research needs

The finding that the GPELF is cost-effective and that it generates significant economic benefits appears robust and consistent across a number of studies. However, there are still important gaps that warrant further research.4

Evaluation of alternative interventions: Although analyses have shown that the current MDA strategies are cost-effective, alternative strategies that may help to achieve the current elimination goals, such as the use of triple-drug therapy,28 other novel drug treatments and vector control,29 should still be investigated.4

Evaluation of MDA strategies in settings coendemic with L. loa: An important ongoing challenge facing lymphatic filariasis elimination efforts are settings coendemic with both onchocerciasis and L. loa, where mass ivermectin distribution is not currently possible.30 Further health economic studies are needed to assess the cost and cost-effectiveness of alternative strategies in such settings.4

Evaluation of neglected tropical disease programme integration: Neglected tropical disease (NTD) programmes are becoming more integrated.31 However, further research is needed as there is currently a lack of understanding of the costs and cost-effectiveness of integrated NTD control programmes.5,6,32

The GPELF would have significant auxiliary benefits on other diseases, such as scabies and the soil-transmitted helminths (STHs).22,33 However, these are typically not considered in these economic evaluations, which would underestimate the cost-effectiveness and cost-benefit of the programme. Likewise, the current economic evaluations for other NTDs are typically looking at one disease at a time.4,17,34,35 However, it would be useful for policy and programme decision-makers who must make resource allocation decisions for the evaluations to consider an integrated NTD control programme package rather than vertical/standalone disease-specific interventions.

Related to this, there is a need to investigate the impact of stopping lymphatic filariasis-related MDA programmes on STH transmission and the potential risk of STH resurgence.36

Diagnostics and surveillance costs: There is a need to evaluate the cost and cost-effectiveness of different diagnostics and surveillance strategies, particularly for post-MDA settings. The importance of this was highlighted in a study by Rao et al.,37 which demonstrated the resurgence of lymphatic filariasis transmission 6 y after stopping MDA.

Morbidity management strategies: A key element of the GPELF involves morbidity management and disability prevention activities.3 However, there are currently only three economic evaluations of lymphatic filariasis-related morbidity management. Turner et al.4 crudely estimated that hydrocele surgery would be classed as highly cost-effective if the surgery cost <$566 and cost-effective if <$398 using the healthcare provider’s perspective. Sowers et al.38 estimated that the ratio of the economic benefit of hydrocele surgery to its cost was 24.8 in Malawi. In addition, Stillwaggon et al.39 estimated that within a lymphedema management programme in India, the average participant would gain lifetime economic benefits 132–165-fold greater than the per-person cost of the programme. Further economic evaluations of potential lymphatic filariasis morbidity management strategies and techniques across a range of settings are still needed.4

The burden of lymphatic filariasis: Further work is needed to improve how the burden of lymphatic filariasis and the subsequent health and economic benefits of interventions are quantified. This includes more accurate estimates of the impact of lymphatic filariasis-related morbidity on productivity, the potential additional disease burden related to mental health, the burden associated with cases’ informal caregivers and quantification of excess mortality associated with clinical disease.4,40,41 A particular area that needs further research is more accurate estimates of the productivity costs for those in informal employment.

Conclusion

Estimates of the cost-effectiveness and economic benefits for a programme as large as the GPELF are subject to notable uncertainty. However, throughout a number of independent studies, the GPELF has consistently been estimated to be cost-effective and generate notable economic benefits.

Author’s contributions: HCT conceived and wrote the manuscript. HCT has undertaken all the duties of authorship and is guarantor of the paper.

Funding: The publication of the papers within this supplement were supported by MSD, GSK and Eisai through the Mectizan Donation Program (MDP) and the Global Alliance for LF Elimination (GAELF). HCT acknowledges funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union.

Competing interests: None declared.

Ethical approval: Not required.

Data availability: No new data were generated or analysed in support of this research.

References

1 World Health Organization. Global Programme to Eliminate Lymphatic Filariasis. Available at http://www.who.int/lymphatic_filariasis/elimination-programme/en/ [accessed 29 July 2020].

2 World Health Organization. PCT database: Lymphatic filariasis. Available at http://www.who.int/neglected_diseases/preventive_chemotherapy/lf/en/ [accessed 29 July 2020].

3 Turner HC, Bettis AA, Chu BK, et al. Investment success in public health: An analysis of the cost-effectiveness and cost-benefit of the Global Programme to Eliminate Lymphatic Filariasis. Clin Infect Dis. 2017;64(6):728–35.

4 Gedge LM, Bettis AA, Bradley MH, et al. Economic evaluations of lymphatic filariasis interventions: a systematic review and research needs. Parasites Vectors. 2018;11(1):75.

5 Goldman AS, Guisinger VH, Akins M, et al. National mass drug administration costs for lymphatic filariasis elimination. PLoS Negl Trop Dis. 2007;1(1):e67.
6 Keating J, Yukich JO, Mollenkopf S, et al. Lymphatic filariasis and onchocerciasis prevention, treatment, and control costs across diverse settings: A systematic review. Acta Trop. 2014;135(0):86–95.

7 Fitzpatrick C, Madin-Warburton M, Schneider T, et al. Benchmarks for the cost per person of mass treatment against neglected tropical diseases: a literature review and metaregression with web-based software application. PLoS Negl Trop Dis. 2016;10(12):e0005037.

8 Remme JHF, Feenstra P, Lever PR, et al. Tropical diseases targeted for elimination: chagas disease, lymphatic filariasis, onchocerciasis, and leprosy. In: Jamison DT, Breman JG, ARs Measham (eds). Disease Control Priorities in Developing Countries. New York: Oxford University Press, 2006, 433–449.

9 Stone CM, Kastner R, Steinmann P, et al. Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage. BMJ Global Health. 2016;1(1):e000021.

10 Horton S, Gelband H, Jamison D, et al. Ranking 93 health interventions for low- and middle-income countries by cost-effectiveness. PLoS One. 2017;12(8):e0182951.

11 Newall AT, Jit M, Hutubessy R. Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines. PharmacoEconomics. 2014;32(6):525–31.

12 Marseille E, Larson B, Kazi DS, et al. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):118–24.

13 Woods B, Revill P, Sculpher M, et al. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19(8):929–35.

14 Shillcutt SD, Walker DG, Goodman CA, et al. Cost effectiveness in low-and middle-income countries: a review of the debates surrounding decision rules. PharmacoEconomics. 2009;27(11):903–17.

15 Leech AA, Kim DD, Cohen JT, et al. Use and misuse of cost-effectiveness analysis thresholds in low- and middle-income countries: trends in cost-per-DALY studies. Value Health. 2018;21(7):759–61.

16 World Health Organization. Contribution of Pharmaceutical Companies to the Control of Neglected Tropical Diseases. Available at http://www.who.int/neglected_diseases/pharma_contribution/en/ [accessed 29 July 2020].

17 Turner HC, Walker M, Pion SDS, et al. Economic evaluations of onchocerciasis interventions: a systematic review and research needs. Trop Med Int Health. 2019;24(7):788–816.

18 Lenk EJ, Redekop WK, Luyendijk M, et al. Productivity loss related to neglected tropical diseases eligible for preventive chemotherapy: a systematic literature review. PLoS Negl Trop Dis. 2016;10(2):e0004397.

19 Ramaiah KD, Das PK, Michael E, et al. The economic burden of lymphatic filariasis in India. Parasitol Today. 2000;16(6):251–3.

20 Gyapong JO, Gyapong M, Evans DB, et al. The economic burden of lymphatic filariasis in northern Ghana. Ann Trop Med Parasitol. 1996;90(1):39–48.

21 Mathew CG, Bettis AA, Chu BK, et al. The health and economic burdens of lymphatic filariasis prior to mass drug administration programs. Clin Infect Dis. 2020;70(12):2561–7.

22 Turner HC, Bettis AA, Chu BK, et al. The health and economic benefits of the Global Programme to Eliminate Lymphatic Filariasis (2000–2014). Infect Dis Poverty. 2016;5(1):54.

23 Chu BK, Hooper PJ, Bradley MH, et al. The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000–2007). PLoS Negl Trop Dis. 2010;4(6):e708.

24 Redekop WK, Lenk EJ, Luyendijk M, et al. The socioeconomic benefit to individuals of achieving the 2020 targets for five preventive chemotherapy neglected tropical diseases. PLoS Negl Trop Dis. 2017;11(11):e0005289.

25 Addiss DG, Brady MA. Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature. Filaria J. 2007;6:2.

26 Ramaiah KD, Guyatt H, Ramu K, et al. Treatment costs and loss of work time to individuals with chronic lymphatic filariasis in rural communities in south India. Trop Med Int Health. 1999;4(1):19–25.

27 Ramaiah KD, Radhamani MP, John KR, et al. The impact of lymphatic filariasis on labour inputs in southern India: results of a multi-site study. Ann Trop Med Parasitol. 2000;94(4):353–64.

28 Thomsen EK, Sanuku N, Baeza M, et al. Efficacy, safety, and pharmacokinetics of co-administered diethylcarbamazine, albendazole, and ivermectin for the treatment of Bancroftian filariasis. Clin Infect Dis. 2016;62(3):334–41.

29 Bockarie MJ, Pedersen EM, White GB, et al. Role of vector control in the global program to eliminate lymphatic filariasis. Annu Rev Entomol. 2009;54:469–87.

30 World Health Organisation. Provisional strategy for interrupting lymphatic filariasis transmission in loiasis-endemic countries: report of the meeting on lymphatic filariasis, malaria and integrated vector management. Geneva: World Health Organization, 2012.

31 World Health Organization. Update on the Global Status of Implementation of Preventive Chemotherapy (PC). Available at https://www.who.int/neglected_diseases/preventive_chemotherapy/PC_Update.pdf [accessed 29 July 2020].

32 Brady MA, Hooper PJ, Ottesen EA. Projected benefits from integrating NTD programs in sub-Saharan Africa. Trends Parasitol. 2006;22(7):285–91.

33 Ottesen EA, Hooper PJ, Bradley M, et al. The Global Programme to Eliminate Lymphatic Filariasis: health impact after 8 years. PLoS Negl Trop Dis. 2008;2(10):e317.

34 Turner HC, Truscott JE, Hollingsworth TD, et al. Cost and cost-effectiveness of soil-transmitted helminth treatment programmes: systematic review and research needs. Parasit Vectors. 2015;8:355.

35 Turner H, French M, Montresor A, et al. Economic evaluations of human schistosomiasis interventions: a systematic review and identification of associated research needs [version 1; peer review: 2 approved]. Wellcome Open Res. 2020;5:45.

36 Means AR, Åsbjörnsdóttir K, Mwandawiro C, et al. Sustaining progress towards NTD elimination: an opportunity to leverage lymphatic filariasis elimination programs to interrupt transmission of soil-transmitted helminths. PLoS Negl Trop Dis. 2016;10(7):e0004737.

37 Rao RJ, Nagodavithana KC, Samarasekera SD, et al. A comprehensive assessment of lymphatic filariasis in Sri Lanka six years after cessation of mass drug administration. PLoS Negl Trop Dis. 2014;8(11):e3281.

38 Sowers L, Stillwaggon E, Chiphwanya J, et al. Economic benefits and costs of surgery for filarial hydrocele in Malawi. PLoS Negl Trop Dis. 2020;14(3):e0008003.

39 Stillwaggon E, Sowers L, Rout J, et al. Economic costs and benefits of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India. Am J Trop Med Hyg. 2016;95(4):877–84.

40 Ton TG, Mackenzie C, Molyneux DH. The burden of mental health in lymphatic filariasis. Infect Dis Poverty. 2015;4:34.

41 Caprioli T, Martindale S, Mengiste A, et al. Quantifying the socio-economic impact of leg lymphoedema on patient caregivers in a lymphatic filariasis and pododeromasis co-endemic district of Ethiopia. PLoS Negl Trop Dis. 2020;14(3):e0008058.